Enprofylline (3-propylxanthine) is a xanthine derivative used in the treatment of asthma, which acts as a bronchodilator. It acts primarily as a competitive nonselective phosphodiesterase inhibitor with relatively little activity as a nonselective adenosine receptor antagonist.[1][2]

Enprofylline
Skeletal formula
Space-filling model of enprofylline
Clinical data
ATC code
  • None
Identifiers
  • 3-Propyl-7H-purine-2,6-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.050.166 Edit this at Wikidata
Chemical and physical data
FormulaC8H10N4O2
Molar mass194.194 g·mol−1
3D model (JSmol)
  • CCCn2c(=O)[nH]c(=O)c1nc[nH]c12
  • InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14) checkY
  • Key:SIQPXVQCUCHWDI-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

References

edit
  1. ^ Lunell E, Svedmyr N, Andersson KE, Persson CG (1982). "Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease". European Journal of Clinical Pharmacology. 22 (5): 395–402. doi:10.1007/bf00542541. PMID 6288396. S2CID 3240010.
  2. ^ Laursen LC (December 1987). "Anti asthmatic effects and pharmacokinetics of enprofylline--a new xanthine derivate". Danish Medical Bulletin. 34 (6): 289–97. PMID 3325233.